Liver transplantation in PBC and PSC: Indications and disease recurrence

Clinics and Research in Hepatology and Gastroenterology

Volumn 35, Issue 6-7, 2011, Pages 446-454

  Carbone, Marco ^a   Neuberger, James ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN; COLESTYRAMINE; CYCLOSPORIN A; GLUCOCORTICOID; HLA DR ANTIGEN; METHOTREXATE; MODAFINIL; OPIATE ANTAGONIST; RIFAMPICIN; SERTRALINE; TACROLIMUS; URSODEOXYCHOLIC ACID;

AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC PROPHYLAXIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL INFECTION; BILE DUCT CARCINOMA; BILIARY TRACT INFECTION; BILIRUBIN BLOOD LEVEL; CADAVER DONOR; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHOLANGITIS; CLINICAL ASSESSMENT TOOL; COLON CANCER; COLON RESECTION; CORTICOSTEROID THERAPY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENTERITIS; FATIGUE; GRAFT SURVIVAL; HEPATIC ENCEPHALOPATHY; HLA MATCHING; HUMAN; ILEITIS; IMMUNOSUPPRESSIVE TREATMENT; INTRACTABLE PRURITUS; LIVER FAILURE; LIVER TRANSPLANTATION; LIVING DONOR; MAINTENANCE THERAPY; MAYO SCORE; PATIENT SELECTION; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRURITUS; QUALITY OF LIFE; RECURRENT DISEASE; RECURRENT INFECTION; RECURRENT PRIMARY BILIARY CIRRHOSIS; RECURRENT PRIMARY SCLEROSING CHOLANGITIS; RISK FACTOR; SEX DIFFERENCE; SHORT SURVEY; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT OUTCOME; VARICOSIS;

EID: 80052340112     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2011.02.007     Document Type: Short Survey

References (131)

1. Adam R, McMaster P, O'Grady JG, Castaing D, Klempnauer JL, Jamieson N, et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 2003;9:1231-43.
2. Rowe IA, Webb K, Gunson BK, Mehta N, Haque S, Neuberger J. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int 2008;21:459-65.
3. United Network for Organ Sharing (UNOS). Available at http://www.unos.org/.
4. Lee J, Belanger A, Doucette JT, et al. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007;5:1313-5.
5. Prince MI, James OF. The epidemiology of primary biliary cirrhosis. Clin Liver Dis 2003;7:795-819.
6. MacQuillan GC, Neuberger J. Liver transplantation for primary biliary cirrhosis. Clin Liver Dis 2003;7:941-56.
7. Corpechot C, Carrat F, Bahr A, et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005;128:297-303.
8. Nordic Liver Transplant Registry. Available at: www.scandiatransplant.org.
9. Brandsaeter B, Broome U, Isoniemi H, et al. Liver transplantation for primary sclerosing cholangitis in the Nordic countries: outcome after acceptance to the waiting list. Liver Transpl 2003;9:961-9.
10. Brandsaeter B, Friman S, Broome U, et al. Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries. Scand J Gastroenterol 2003;38:1176-83.
11. Futagawa Y, Terasaki PI. An analysis of the OPTN/UNOS Liver Transplant Registry. Clin Transpl 2004;18:315.
12. Kashyap R, Safadjou S, Chen R, Mantry P, Sharma R, Patil V, et al. Living donor and deceased donor liver transplantation for autoimmune and cholestatic liver diseases - an analysis of the UNOS Database. J Gastrointest Surg 2010;14:1362-9.
13. Christensen E, Gunson B, Neuberger J. Optimal timing of liver transplantation for patients with primary biliary cirrhosis: use of prognostic modelling. J Hepatol 1999;30(2):285-92.
14. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. European Association for the Study of the Liver. J Hepatol 2009;51:237-267.
15. Leuschner U. Primary biliary cirrhosisd presentation and diagnosis. Clin Liver Dis 2003;7:741-58.
16. Huet PM, Deslauriers J, Tran A, Faucher C, Charbonneau J. Impact of fatigue on the quality of life of patients with primary biliary cirrhosis. Am J Gastroenterol 2000;95:760-7.
17. Cauch-Dudek K, Abbey S, Stewart DE, Heathcote EJ. Fatigue in primary biliary cirrhosis. Gut 1998;43:705-10.
18. Miller ER, Hiller JE, Shaw DR. Quality of life in HCV-infection: lack of association with ALT levels. Aust N Z J Public Health 2001;25:355-61.
19. Jones EA. Fatigue associated with chronic liver disease: a riddle wrapped in a mystery inside an enigma. Hepatology 1995;22:1606-8.
20. Jones EA, Yurdaydin C. Is fatigue associated with cholestasis mediated by altered central neurotransmission? Hepatology 1997;25:492-4.
21. Bergasa NV, Jones EA. The pruritus of cholestasis: potential pathogenic and therapeutic implications of opioids. Gastroenterology 1995;108:1582-8.
22. Jones EA, Bergasa NV. The pruritus of cholestasis: from bile acids to opiate agonists. Hepatology 1990;11:884-7.
23. Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. BMJ 1988;297:1501-4.
24. Burak KW, Le T, Swain MG. Increased sensitivity to the locomotor-activating effects of corticotropin-releasing hormone in cholestatic rats. Gastroenterology 2002;122: 681-8.
25. Bjornsson E et al. Fatigue measurements in patients with primary biliary cirrhosis and the risk of mortality during follow-up. Liver Int 2010;30(2):251-8 [doi:10.1111/j.1478-3231.2009.02160.x].
26. Jones DE, Al-Rifai A, Frith J, Patanwala I, Newton JL. The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: results of a 9-year follow-up. J Hepatol 2010;53:911-7.
27. Prince MI, et al. Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo-controlled, cross-over trial. Aliment Pharmacol Ther 2003;17(70):137-43.
28. Ter Borg PC, van Os E, van den Broek WW, Hansen BE, van Buuren HR. Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomized controlled trial [iSRCTN88246634]. BMC Gastroenterol 2004;4:13.
29. Talwalkar JA, et al. Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial. Dig Dis Sci 2006;51:1985-91.
30. Theal JJ, et al. A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. Hepatology 2005;41:1305-12.
31. Battezzati PM, et al. Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. Aliment Pharmacol Ther 2001;15:1427-34.
32. Ian Gan S, de Jongh M, Kaplan MM. Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience. Dig Dis Sci 2009;54:2242-6.
33. Babatin MA, Sanai FM, Swain MG. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy. Aliment Pharmacol Ther 2006;24:813-20.
34. Gross CR, Malinchoc M, Kim WR, et al. Quality of life before and after liver transplantation for cholestatic liver disease. Hepatology 1999;29:356-64.
35. Bergasa NV. The pruritus of cholestasis. J Hepatol 2005;43:1078-88.
36. Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int 2006;26:943-8.
37. Tandon P, Rowe BH, Vandermeer B, Bain VG. The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol 2007;102:1528-36.
38. Bergasa NV. Pruritus in primary biliary cirrhosis: pathogenesis and therapy. Clin Liver Dis 2008;12:385-406.
39. Boberg KM, Rocca G, Egeland T, et al. Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis. Hepatology 2002;35: 652-7.
40. Kim WR, Poterucha JJ, Wiesner RH, et al. The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology 1999;29:1643-8.
41. Ricci P, Therneau TM, Malinchoc M, et al. A prognostic model for the outcome of liver transplantation in patients with cholestatic liver disease. Hepatology 1997;25(3):672-7.
42. Chapman R, Fevery J, Kalloo A, Nagorney DM, Muri Boberg K, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis - AASLD practice guidelines. Hepatology 2010;51:2.
43. Tischendorf JJ, Hecker H, Kruger M, Manns MP, Meier PN. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol 2007;102(1):107-14.
44. Stiehl A, Rudolph G, Kloters-Plachky P, Sauer P, Walker S. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002;36(2):151-6.
45. Okolicsanyi L, Fabris L, Viaggi S, Carulli N, Podda M, Ricci G. Primary sclerosing cholangitis: clinical presentation, natural history and prognostic variables: an Italian multicentre study. Eur J Gastroenterol Hepatol 1996;8(7):685-91.
46. Abraham SC, Kamath PS, Eghtesad B, Demetris AJ, Krasinskas AM. Liver transplantation in precirrhotic biliary tract disease: portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy. Am J Surg Pathol 2006;30:1454-61.
47. Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Loof L, Danielsson A, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36:321-7.
48. Gores GJ. Early detection and treatment of cholangiocarinoma. Liver Transpl 2000;6:S30-4.
49. Ahrendt SA, Pitt HA, Nakeeb A, et al. Diagnosis and management of cholangiocarcinoma in primary sclerosing cholangitis. J Gastrointest Surg 1999;3(4):357-67 [discussion 367-368].
50. Bjornsson E, Angulo P. Cholangiocarcinoma in young individuals with and without primary sclerosing cholangitis. Am J Gastroenterol 2007;102(8):1677-82.
51. Jonas S, Mittler J, Pascher A, Theruvath T, Thelen A, Klupp J, et al. Extended indications in living-donor liver transplantation: bile duct cancer. Transplantation 2005;80(Suppl. 1):S101-4.
52. Lang H, Kaiser G, Zopf T, Sotiropoulos GC, Frilling A, Malago M, et al. Surgical therapy of hilar cholangiocarcinoma. Chirurg 2006;77:325-34.
53. Lang H, Sotiropoulos GC, Dömland M, Frühauf NR, Paul A, Kind EM, et al. Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC) - when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg 2005;241:134-43.
54. Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 2000;69:1633-7.
55. Pichlmayr R,Weimann A, Klempnauer J, Oldhafer KJ, Maschek H, Tusch G, et al. Surgical treatment in proximal bile duct cancer: a single-center experience. Ann Surg 1996;224:628-38.
56. Rea JG, Heimback JK, Rosen CB, Gores GJ, Haddock MG, Alberts SR, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005;242:451-8.
57. Shimoda M, Farmer DG, Colquhoun SD, Rosove M, Ghobrial RM, Yersiz H, et al. Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature. Liver Transpl 2001;7:1023-33.
58. Sudan D, DeRoover A, Chinnakotla S, Fox I, Shaw B, McCashland T, et al. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant 2002;2:774-9.
59. De Vreede I, Steers JL, Burch PA, Rosen CB, Gunderson LL, Haddock MG, et al. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transplant 2000;6: 317-9.
60. Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Pedersen R, Kremers W, et al. Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation 2006;82(12):1703-7.
61. Gores GJ, Gish RG, Sudan D, Rosen CB, and the MELD Exception Study Group. Model for End-Stage Liver Disease (MELD) exception for cholangiocarcinoma or biliary dysplasia. Liver Transplantation 2006;12:S95-7.
62. Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991;11:31-9.
63. Takikawa H, Manabe T. Primary sclerosing cholangitis in Japan - analysis of 192 cases. J Gastroenterol 1997;32:134-7.
64. Broome U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Sem Liv Dis 2006;26:31-41.
65. Loftus Jr EV, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005;54:91-6.
66. Papatheodoridis GV, Hamilton M, Mistry PK, et al. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 1998;43:639-44.
67. Van de Vrie W, de Man RA, van Buuren HR, et al. Inflammatory bowel disease and liver transplantation for primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 2003;15:657-63.
68. Dvorchik I, Subotin M, Demetris AJ, et al. Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology 2002;35: 380-4.
69. Ho GT, Seddon AJ, Therapondos G, et al. The clinical course of ulcerative colitis after orthotopic liver transplantation for primary sclerosing cholangitis: further appraisal of immunosuppression post transplantation. Eur J Gastroenterol Hepatol 2005;17:1379-85.
70. Haagsma EB, Van Den Berg AP, Kleibeuker JH, et al. Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens. Aliment Pharmacol Ther 2003;18:33-44.
71. Befeler AS, Lissoos TW, Schiano TD, et al. Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation 1998;65:393-6.
72. Gavaler JS, Delemos B, Belle SH, et al. Ulcerative colitis disease activity as subjectively assessed by patient-completed questionnaires following orthotopic liver transplantation for sclerosing cholangitis. Dig Dis Sci 1991;36:321-8.
73. Shaked A, Colonna JO, Goldstein L, et al. The interrelation between sclerosing cholangitis and ulcerative colitis in patients undergoing liver transplantation. Ann Surg 1992;215:598-603. Discussion 604-5.
74. Vera A, Gunson BK, Ussatoff V, Nightingale P, Candinas D, Radley S, et al. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation 2003;75:1983-8.
75. Fabia R, Levy MF, Testa G, Obiekwe S, Goldstein RM, Husberg BS, et al. Colon carcinoma in patients undergoing liver transplantation. Am J Surg 1998;176:265-9.
76. Gorgun E, Remz FH, Manilich E, et al. Surgical outcome in patients with primary sclerosing cholangitis undergoing ileal pouch-anal anastomosis: a case control study. Surgery 2005;138:631.
77. Cho CS, Dayton MT, Thompson JS. Proctocolectomy-ileal pouch-anal anastomosis for ulcerative colitis after liver transplantation for primary sclerosing cholangitis: a multiinstitutional analysis. J Gastrointest Surg 2008;12:1221.
78. Bosso MC, Marchesa PE, Ricchiuti A, Giacardi A, Cocchis D, Campi M, et al. Proctocolectomy for ulcerative colitis after liver transplantation for primary sclerosing cholangitis. Transplant Proc 2009;41(4):1390-2.
79. Kartheuser AH, Dozois RR, LaRusso NF, Wiesner RH, Ilstrup DM, Schleck CD. Comparison of surgical treatment of ulcerative colitis associated with primary sclerosing cholangitis: ileal pouch-anal anastomosis versus Brooke ileostomy. Mayo Clin Proc 1996;71:748-56.
80. Stahlberg D, Veress B, Tribukait B, Broome U. Atrophy and neoplastic transformation of the ileal pouch mucosa in patients with ulcerative colitis and primary sclerosing cholangitis: a case control study. Dis Colon Rectum 2003;46:770-8.
81. Vera A, Moledina S, Gunson B, Hubscher S, Mirza D, Olliff S, et al. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 2002;360:1943-4.
82. Neuberger J, Portmann B, Macdougall BR, Calne RY, Williams R. Recurrence of primary biliary cirrhosis after liver transplantation. N Engl J Med 1982;306:1-4.
83. Mitchison HC, Palmer JM, Bassendine MF, et al. A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. J Hepatol 1992;15:336-44.
84. Rautiainen H, Karkkainen P, Karvonen AL, et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 2005;41:747-52.
85. Christensen E, Neuberger J, Crowe J, et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology 1985;89:1084-91.
86. LiermannGarcia RF, Evangelista Garcia C, McMaster P, Neuberger J. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology (Baltimore MD) 2001;33:22-7.
87. Charatcharoenwitthaya P, Pimentel S, Talwalkar JA, et al. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2007;13:1236-45.
88. Abu-Elmagd K, Demetris J, Rakela J, et al. Transplantation for primary biliary cirrhosis: disease recurrence and outcome in 421 patients. Hepatology 1997;26:176A.
89. Sanchez EQ, Levy MF, Goldstein RM, et al. The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation. Transplantation 2003;76: 1583-8.
90. Levitsky J, Hart J, Cohen SM, Te HS. The effect of immunosuppressive regimens on the recurrence of primary biliary cirrhosis after liver transplantation. Liver Transpl 2003;9:733-6.
91. Khettry U, Anand N, Faul PN, et al. Liver transplantation for primary biliary cirrhosis: a long-term pathologic study. Liver Transpl 2003;9:87-96.
92. Sebagh M, Farges O, Dubel L, Samuel D, Bismuth H, Reynes M. Histological features predictive of recurrence of primary biliary cirrhosis after liver transplantation. Transplantation 1998;65:1328-33.
93. Jacob DA, Bahra M, Schmidt SC, et al. Mayo risk score for primary biliary cirrhosis: a useful tool for the prediction of course after liver transplantation? Ann Transplant 2008;13:35-42.
94. Neuberger J, Gunson B, Hubscher S, Nightingale P. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2004;4:488-91.
95. Jacob DA, Neumann UP, Bahra M, et al. Long-term followup after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients. Clin Transplant 2006;20: 211-20.
96. Sylvestre PB, Batts KP, Burgart LJ, Poterucha JJ, Wiesner RH. Recurrence of primary biliary cirrhosis after liver transplantation: histologic estimate of incidence and natural history. Liver Transpl 2003;9:1086-93.
97. Abraham SC, Poterucha JJ, Rosen CB, Demetris AJ, Krasinskas AM. Histologic abnormalities are common in protocol liver allograft biopsies from patients with normal liver function tests. Am J Surg Pathol 2008;32:965-73.
98. Klein R, Huizenga JR, Gips CH, Berg PA. Antimitochondrial antibody profiles in patients with primary biliary cirrhosis before orthotopic liver transplantation and titres of antimitochondrial antibody-subtypes after transplantation. J Hepatol 1994;20:181-9.
99. Demetris AJ, Markus BH, Esquivel C, et al. Pathologic analysis of liver transplantation for primary biliary cirrhosis. Hepatology 1988;8:939-47.
100. Mells G, Mann C, Hubscher S, Neuberger J. Late protocol liver biopsies in the liver allograft: a neglected investigation? Liver Transpl 2009;15:931-8.
101. Wong PY, Portmann B, O'Grady JG, et al. Recurrence of primary biliary cirrhosis after liver transplantation following FK506-based immunosuppression. J Hepatol 1993;17:284-7.
102. Hubscher SG, Elias E, Buckels JA, Mayer AD, McMaster P, Neuberger JM. Primary biliary cirrhosis. Histological evidence of disease recurrence after liver transplantation. J Hepatol 1993;18:173-84.
103. Hashimoto E, Shimada M, Noguchi S, et al. Disease recurrence after living liver transplantation for primary biliary cirrhosis: a clinical and histological follow-up study. Liver Transpl 2001;7:588-95.
104. Minuk GY, Bohme CE, Burgess E, Hershfield NB, Kelly JK, Shaffer EA, et al. Pilot study of cyclosporine A in patients with symptomatic primary biliary cirrhosis. Gastroenterology 1988;95:1356-63.
105. Lunz JG, Contrucci S, Ruppert K, Murase N, Fung JJ, Starzl TE, et al. Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection. Am J Pathol 2001;158:1379-90.
106. Minder D, Boni J, Schupbach J, Gehring H. Immunophilins and HIV-1 infection. Arch Virol 2002;147:1531-42.
107. Kantrow SP, Gierman JL, Jaligman VR, Zhang P, Piantadosi CA, Summer WR, et al. Regulation of tumour necrosis factor for cytotoxicity by calcineurin. FEBS Lett 2000;483:119-24.
108. Elmore SP, Qian T, Grissom SF, Lemasters JJ. The mitochondrial permeability transition initiates autophagy rat hepatocytes. FASEB J 2001;15:2286-7.
109. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006;12:1813-24.
110. Manousou P, Arvaniti V, Tsochatzis E, Isgro G, Jones K, Shirling G, et al. Primary biliary cirrhosis after liver transplantation: influence of immunosuppression and human leukocyte antigen locus disparity. Liver Transplantation 2010;16:64-73.
111. Dmitrewski J, Hubscher SG, Mayer AD, Neuberger JM. Recurrence of primary biliary cirrhosis in the liver allograft: the effect of immunosuppression. J Hepatol 1996;24:253-7.
112. Campsen J, Zimmerman M, Trotter J, et al. Liver transplantation for primary biliary cirrhosis: results of aggressive corticosteroid withdrawal. Transplant Proc 2009;41:1707-12.
113. Morioka D, Egawa H, Kasahara M, Jo T, Sakamoto S, Ogura Y, et al. Impact of human leukocyte antigen mismatching on outcomes of living donor liver transplantation for primary biliary cirrhosis. Liver Transpl 2007;13:80-90.
114. Guy JE, Qian P, Lowell JA, Peters MG. Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant. Liver Transpl 2005;11:1252-7.
115. Balan V, Ruppert K, Demetris AJ, et al. Long-term outcome of human leukocyte antigen mismatching in liver transplantation: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Hepatology (Baltimore MD) 2008;48:878-88.
116. Hashimoto T, Sugawara Y, Makuuchi M. Impact of human leukocyte antigen mismatching on outcomes of living donor liver transplantation for primary biliary cirrhosis. Liver Transpl 2007;13:938-9.
117. Lerut J, Demetris AJ, Stieber AC, Marsh JW, Gordon RD, Esquivel CO, et al. Intrahepatic bile duct strictures after human orthotopic liver transplantation. Recurrence of primary sclerosing cholangitis or unusual presentation of allograft rejection? Transpl Int 1988;1:127-30.
118. Harrison RF, Davies MH, Neuberger JM, Hubscher SG. Fibrous and obliterative cholangitis in liver allografts: evidence of recurrent primary sclerosing cholangitis? Hepatology 1994;20:356-61.
119. Sheng R, Campbell WL, Zajko AB, Baron RL. Cholangiographic features of biliary strictures after liver transplantation for primary sclerosing cholangitis: evidence of recurrent disease. AJR Am J Roentgenol 1996;166:1109-13.
120. Graziadei IW, Wiesner RH, Marotta PJ, Porayko MK, Hay JE, Charlton MR, et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999;30:1121-7.
121. Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Steinberg T, et al. Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl 2008;14:181-5.
122. Alabraba E, Nightingale P, Gunson B, Hubscher S, Olliff S, Mirza D, et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl 2009;15:330-40.
123. Oya H, Sato Y, Yamamoto S, Takeishi T, Kobayashi T, Hatakeyama K. Living related donor liver transplantation for primary sclerosing cholangitis with hepatocellular carcinoma and Crohn's disease: a case report. Transplant Proc 2004;36:2297-8.
124. Kaibori M, Uemoto S, Fujita S, Inomata Y, Egawa H, Asonuma K, et al. Native hepatectomy after auxiliary partial orthotopic liver transplantation. Transpl Int 1999;12:383-6.
125. Ikegami T, Nishizaki T, Yanaga K, Kakizoe S, Nomoto K, Ohta R, et al. Living-related auxiliary partial orthotopic liver transplantation for primary sclerosing cholangitis: subsequent removal of the native liver. Hepatogastroenterology 1999;46:2951-4.
126. Nakamura M, Fuchinoue S, Nakajima I, Kitajima K, Tojimbara T, Takasaki K, et al. Three cases of sequential liver-kidney transplantation from living-related donors. Nephrol Dial Transplant 2001;16:166-8.
127. Alexander J, Lord JD, Yeh MM, Cuevas C, Bakthavatsalam R, Kowdley KV. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2008;14:245-51.
128. Cholongitas E, Shusang V, Papatheodoridis GV, Marelli L, Manousou P, Rolando N, et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2008;14:138-43.
129. Egawa H, Taira K, Teramukai S, et al. Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation: a single center experience. Dig Dis Sci 2009;54(6):1347-54.
130. Maheshwari A, Yoo HY, Thuluvath PJ. Long-term outcome of liver transplantation in patients with PSC: a comparative analysis with PBC. Am J Gastroenterol 2004;99(3):538-42.
131. Demetris AJ, Adeyi O, Bellamy CO, Clouston A, Charlotte F, Czaja A, et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006;44:489-501.